Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of motor neurons that leads to progressive muscle wasting and weakness, with a typical survival time of three to five years from onset…
With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary…
No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current…
The maturing, but highly lucrative, market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is becoming increasingly fragmented as attractive new options enter a powerful…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disease characterized by skin fibrosis and varying degrees of vasculopathy manifesting as Raynaud’s disease and, often,…
An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS…
The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years,…
Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and…
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…
Neuropathic pain (NP) is a prominent form of pain associated with a variety of diseases and conditions, including cancer, diabetes, herpes zoster, chronic back pain, and multiple sclerosis. A…
The wide array of disease-modifying therapies (DMTs) now available for the treatment of multiple sclerosis (MS) in the major European markets (EU5; France, Germany, Italy, Spain, and the United…
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg 3TW, oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision-making and treatment choice in the…
U.S. Prescriber and Payer Perspective on Current Mainstays, Recent Launches, Late-Stage Products, and the First Generic Competitors The array of disease-modifying therapies (DMTs) approved for the…
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg three times weekly (3TW), Plegridy, Lemtrada, oral DMTs—has complicated clinical decision-making and treatment choice…